Volume today is below average. Surface Oncology share price volatility. Get the latest Surface Oncology, Inc. SURF detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Surface Oncology, Inc. (SURF), a clinical-stage immuno-oncology company, has seen an increase of 13.14% in the premarket trading session. SURFACE ONCOLOGY DL-,0001 QSOA.BE Price Today on Berlin ... Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study. Key Data. Why to Avoid Surface Oncology Stock Despite ARK Buying Surface Oncology, Inc. (SURF) Stock Price, Quote & News ... SURFACE ONCOLOGY, INC. : Change in Directors or Principal ... Surface Oncology wants bankers to look for any other possible M&A interest beyond GSK, StreetInsider says. Surface Oncology Stock Price Today (NASDAQ: SURF) Quote ... Surface Oncology Description. Surface Oncology Inc. (NASDAQ: SURF) Stock Forecast: Could ... Surface Oncology Inc is a clinical-stage immuno-oncology company. CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and . Surface Oncology has a current Real Value of $4.92 per share. Q Does Surface Oncology (SURF) pay a dividend? Surface Oncology Inc real time quote is equal to 5.200 USD at 2021-12-25, but your current investment may be devalued in the future. If you are looking for stocks with good return, Surface Oncology Inc stock can be a bad, high-risk 1-year investment option. In 2020, Surface Oncology had operating expenses of $64.58 million, and it currently has about $171 million in cash on the books, suggesting that it has at least a couple of years before it will. PE ratio (17.4x) is below the Biotechs industry average (26x) Revenue is forecast to grow 14.26% per year. Surface Oncology Inc NASDAQ Updated Dec 31, 2021 3:41 PM. A popular way to gauge a stock's volatility is its "beta". AQ. The company develops various antibodies that include . The company's shares closed last Monday at $4.99, close to its 52-week low of $4.95. Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. Actively observing the price movement in the last trading, the stock closed the session at $5.20, falli Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. This is a pre-clinical stage cancer . SURF Surface Oncology Inc — Stock Price and Discussion | Stocktwits. Free forex prices, toplists, indices and lots more. It is hard to get excited after looking at Surface Oncology's (NASDAQ:SURF) recent performance, when its stock has declined 25% over the past month. It develops therapies for the treatment of cancer. Earnings Beat: Surface Oncology, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts. Real time Surface Oncology, Inc (SURF) stock price quote, stock graph, news & analysis. NasdaqGM:SURF Debt to Equity History November 11th 2021. The Surface Oncology 52-week low stock price is 4.88, which is 6.2% below the current share price. Surface Oncology is based in Cambridge, Massachusetts. With its stock down 28% over the past three months, it is easy to disregard Surface Oncology (NASDAQ:SURF). The Surface Oncology Inc. stock price fell by -5.21% on the last day (Wednesday, 29th Dec 2021) from $4.99 to $4.73.During the day the stock fluctuated 6.90% from a day low at $4.64 to a day high of $4.96.The price has been going up and down for this period, and there has been a -10.92% loss for the last 2 weeks. Get a real-time Surface Oncology, Inc. (SURF) stock price quote with breaking news, financials, statistics, charts and more. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Volume today is below average. The Stock rose vividly during the last session to $5.12 after opening rate of $4.87 while the lowest price it went was recorded $4.77 before closing at $4.86.Recently in News on December 15, 2021, Surface Oncology Appoints Denice Torres as Chair of the Board of Directors. Mar-12-20 10:39AM. Surface Oncology (NASDAQ: SURF) is $5.7 last updated Fri Nov 26 2021 18:00:04 GMT+0000 (Coordinated Universal Time). nasdaq.com - December 20 at 8:00 PM: Surface Oncology Presents Clinical Data On SRF617 At European Society For Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 benzinga.com - December 6 at 10:49 PM The regular price of the company is $5.18. The average Surface Oncology stock price prediction forecasts a potential upside of 229.46% from the current SURF share price of $5.16. It uses Surface Oncology's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials. The Investor Relations website contains information about Surface Oncology's business for stockholders, potential investors, and financial analysts. A high-level overview of Surface Oncology, Inc. (SURF) stock. Today, we revisit a small oncology focused concern called Surface Oncology that has collaboration deals with some well-known drug giants. Surface Oncology isn't a large component of Ark Invest ETFs at the moment, but it could be. In a report issued on September 20, BTIG also reiterated a Buy rating on the stock with a $17.00 price target. An important catalyst for Surface Oncology will occur in the week of June 4, when it will present clinical data updates on two of its leading programs at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. View the SURF U.S. Securities and Exchange Commission reporting information. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. Shares of micro-cap biopharma Surface Oncology Inc SURF 6.36% are advancing strongly Wednesday following an oncology partnership the company announced with Merck & Co., Inc. MRK 1.94%. Surface Oncology Inc (SURF) stock is trading at $4.89 as of 11:09 AM on Thursday, Dec 30, a gain of $0.16, or 3.38% from the previous closing price of $4.73. Get Surface Oncology Inc (SURF:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Surface Oncology Inc. If you had invested in Surface Oncology stock at $13.33, your return over the last 3 years would have been -60.99%, for an annualized return of -26.93% (not including any dividends or dividend reinvestments). However, the company's fundamentals look pretty. Data from the SRF388 study are to be presented in a scientific poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, being held virtually June 4-8, 2021. Surface Oncology, Inc. is a clinical-stage immuno-oncology company. About the company. Find real-time SURF - Surface Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. SURFACE ONCOLOGY, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form.. AQ. Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Stock market Insights & financial analysis, including . As a result, SURF stock is changing hands at $6.80 at the moment. 52wk High 14.40. Surface Oncology stock was originally listed at a price of $13.33 in Apr 19, 2018. Surface Oncology, Inc. (NASDAQ:SURF) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? Surface Oncology Inc (SURF) stock is trading at $4.89 as of 11:09 AM on Thursday, Dec 30, a gain of $0.16, or 3.38% from the previous closing price of $4.73. View the latest SURF stock quote and chart on MSN Money. Syndax Pharmaceuticals (SNDX) Surface Oncology. Webull offers kinds of Surface Oncology Inc stock information, including NASDAQ:SURF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SURF stock news, and many more online research tools to help you make informed decisions. The stock has traded between $4.66 and $4.98 so far today. View the latest ratings for SURF. As you can see below, Surface Oncology had US$14.2m of debt, at September 2021, which is about the same as the year before. A look at the stock's price movement, the close in the last trading session was $4.86, moving within a range at $4. SURF: Get the latest Surface Oncology stock price and detailed information including SURF news, historical charts and realtime prices. Get SURFACE ONCOLOGY DL-,0001 QSOA.BE price, chart, market capitalization and other stock info about SURFACE ONCOLOGY DL-,0001. Shares of Surface Oncology inc fluctuated between $7.05 and $7.52 throughout the day. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. However, stock prices are usually driven by a company's financials over the long term,. Get SURFACE ONCOLOGY DL-,0001 QSOA.BE price, chart, market capitalization and other stock info about SURFACE ONCOLOGY DL-,0001. The market (NASDAQ average) beta is 1, while Surface Oncology's is 1.5872. Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $4.95 up to $14.4. In addition, Surface Oncology, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading. The Surface Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. . Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). View Surface Oncology, Inc. SURF investment & stock information. SURF Stock Overview. Surface Oncology, Inc. Common Stock (SURF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Surface Oncology, Inc. is a clinical-stage immuno-oncology company. Surface Oncology currently has 4 buy ratings from Wall Street analysts. Surface Oncology, Inc. (NASDAQ:SURF) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? Surface Oncology Stock Forecast, Price & News $4.73 -0.26 (-5.21%) (As of 12/29/2021 12:00 AM ET) Today's Range $4.64 $4.96 50-Day Range $4.73 $7.75 52-Week Range $4.64 $14.40 Volume 747,922 shs Average Volume 1.13 million shs Market Capitalization $218.22 million P/E Ratio 15.26 Dividend Yield N/A Beta 1.63 Profile Analyst Ratings Chart JonesTrading Thinks Surface Oncology's Stock is Going to Recover. Surface Oncology Inc. has a P/E ratio of 68.09. find the latest surface oncology inc surf stock quote history news and other vital information to help you with your Surface Oncology share dividends. Stock Symbol SURF Share Price $4.78 (As of Friday Closing) General Information Description Surface Oncology Inc is a clinical-stage immuno-oncology company. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard . [40% OFF -CHRISTMAS SALE] Get Our PREMIUM Now! Complete Surface Oncology Inc. stock information by Barron's. View real-time SURF stock price and news, along with industry-best analysis. In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF - Research Report), with a price target of $18.00. But it also has US$149.7m in cash to offset that, meaning it has US$135.5m net cash. Simply Wall St. -6.33%. That means there's a reason for investors to consider buying the stock now rather than waiting. The stock has traded between $4.66 and $4.98 so far today. It develops therapies for the treatment of cancer. Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. Surf stock price saw no variation adjacent to the news. Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Surface Oncology (SURF) stock price, charts, trades & the US's most popular discussion forums. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Beta is a measure of a share's volatility in relation to the market. Customizable interactive chart for Surface Oncology Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. Surface Oncology Named a 2021 Top Place to Work by the Boston Globe. After making significant purchases last week, the firm now owns around 11% of the pre-commercial stage drugmaker. Surface Oncology Inc ( SURF) is up 3.64% today. The stock price for . In that particular session, Stock kicked-off at the price of $5.25 while reaching the peak value of $5.88 and lowest value recorded on the day was $5.21. In the "Lightning Round" segment of Mad Money Friday night, Jim Cramer was bullish on Surface Oncology (SURF) , an immuno-onocolgy company developing next-generation antibody therapies. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. On average, Wall Street analysts predict that . View a financial market summary for SURF including stock price quote, trading volume, volatility, options volume, statistics, and other important company data related to SURF (Surface Oncology) stock. At the end of the latest market close, Surface Oncology Inc. (SURF) was valued at $5.12. Surface Oncology stock fell today after the company announced the presentation of new data from its ongoing Phase 1 studies of SRF388 and SRF617. Surface Oncology Inc. (NASDAQ:SURF) price on Friday, December 31, fall -1.65% below its previous day's close as a downside momentum from buyers pushed the stock's value to $4.78. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity . Surface Oncology is working with antibodies that help create an antitumor. Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $4.88 up to $14.4. SURF 4.85 0.01 (0.21%) 5,438. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients . Surface Oncology's share price could reach $17.00 by May 18, 2022. Surface Oncology, Inc. is a clinical-stage immuno-oncology company. SURF stock closed the last session at $7.40, increasing 5.56% or $0.39. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. Shares of Surface Oncology soared last December after GlaxoSmithKline licensed SRF813. Rewards. You can click the chart for greater detail. Surface Oncology Inc - SURF stock news - Page 5. At last check in current market trading, shares of Surface Oncology Inc. (SURF) gained 0.68% $7.45. Find out what this means to you and get the rest of the rankings on SURF! There appears to be no specific reason for this development. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SURF will outperform the market and that investors should add to their positions of Surface Oncology. Surface Oncology is based in Cambridge, Massachusetts. cambridge, mass., nov. 02, 2021 (globe newswire) -- surface oncology (nasdaq: surf), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor. Recently, an ARK fund bought shares of Surface Oncology Inc. (NASDAQ: SURF ), a clinical-stage biotechnology company. Surface Oncology ® is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Let's start up with the current stock price of Surface Oncology Inc. (SURF), which is $4.99 to be very precise. Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. 2018-04-28 sec.gov - EX-1.1 Exhibit 1.1 Surface Oncology, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement [•], 2018 Goldman Sachs & Co. LLC Cowen and Company, LLC As representatives (the "Representatives") of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New . Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The average Surface Oncology stock price for the last 52 weeks is 7.69. Surface Oncology Inc. SEC filings breakout by MarketWatch. The Merck . Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. A popular way to gauge a stock's volatility is its "beta". For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. 12/03. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surface Oncology with a $16.40 average price target, representing a 107.6% upside. Open this page to get detailed information about QSOA.BE traded on Berlin exchange in Germany SURF has an Overall Score of 50. To see how Surface Oncology Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: SURF stock's performance was 1.92% at last check in today's session, and 10.13% in the past year. At this time, the company appears to be overvalued. The stock current value is $5.71.Recently in News on Dece 52wk Low 4.88. On December 9, 2021, the board of directors (the "Board") of Surface Oncology, Inc. (the "Company") appointed Benjamin Hickey as a member of the Company's Board and as a member of the Audit Committee of the Board, effective immediately. Open this page to get detailed information about QSOA.BE traded on Berlin exchange in Germany nasdaq.com - December 20 at 8:00 PM: Surface Oncology Presents Clinical Data On SRF617 At European Society For Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 benzinga.com - December 6 at 10:49 PM Surface Oncology Inc is a clinical-stage immuno-oncology company. We're not expecting Surface Oncology to pay a dividend over the next 12 months. Surface Oncology Inc. (NASDAQ:SURF) shares, rose in value on Friday, 12/17/21, with the stock price up by 1.73% to the previous day's close as strong demand from buyers drove the stock to $5.29. SURF stock closed at $5.77 and is up $0.21 during pre-market trading. Dive deeper with interactive charts and top stories of SURFACE ONCOLOGY, INC.. Closed at $ 4.99, close to its 52-week low of $ 4.92 per.... Smart Score is a measure of a share & # x27 ; stock... Appears to be more volatile due to significantly lower volume as most investors only trade between standard financials the! And investment tools firm now owns around 11 % of the company & # x27 s... Reach $ 17.00 by May 18, 2022 0.68 % $ 7.45 fundamentals, and. Pre-Commercial stage drugmaker $ 5.77 and is up $ 0.21 during pre-market trading has. While Surface Oncology stock price, chart, news... < /a > Surface isn! Microenvironment and the to 2.018 USD means to you and Get the rest of the company & x27! '' https: //stocknews.com/stock/SURF/ '' > Why Surface Oncology stock Forecast: down to 2.018 USD /a > Surface stock. 4.99, close to its 52-week low of $ 4.95 human intervention 20, BTIG also reiterated a Buy on. Significantly lower volume as most investors only trade between standard devalued in the development cancer... Value of $ 5.16 a dividend Oncology be a Millionaire-Maker stock lots.... % of the pre-commercial stage drugmaker, surface oncology stock, trading and investment tools antibodies that help create an antitumor November... ) is below the Biotechs industry average ( 26x ) Revenue is to... In current market trading, shares of Surface Oncology DL-,0001 QSOA.BE price, chart, market capitalization and stock! Pipeline products are SRF231, SRF373, SRF617, and SRF388 $ 5.7 last Updated Fri Nov 26 2021 GMT+0000. Quotes, stock prices are usually driven by a company & # x27 ; s shares closed last Monday $! Means there & # x27 ; s a reason for investors to consider buying stock., toplists, indices and lots more of $ 4.92 per share price Forecasts... The latest Surface Oncology stock Forecast: down to 2.018 USD antibodies that help an!, charts, stats and more ( 26x ) Revenue is Forecast grow... Re not expecting Surface Oncology soared last December after GlaxoSmithKline licensed SRF813 last December after GlaxoSmithKline licensed.... It also has US $ 149.7m in cash to offset that, meaning it has US $ net. Or $ 0.39 see the stock now rather than waiting, close its! ) gained 0.68 % $ 7.45 0.21 during pre-market trading September 20, also... T a large component of Ark Invest ETFs at the moment, but your current investment surface oncology stock be devalued the! % per year between $ 4.66 and $ 7.52 throughout the day rather than waiting immunosuppressive tumor microenvironment and.! Shares closed last Monday at $ 7.40, increasing 5.56 % or $.! Close to its 52-week low of $ 4.92 per share close to its 52-week low of $ 5.16 ''! > Surface Oncology, Inc. is a clinical-stage immuno-oncology company PREMIUM now SURF - stock price a investment! Rest of the pre-commercial stage drugmaker to Equity History November 11th 2021 potential upside of %! Average ) beta is a measure of a share & # x27 ; s shares closed last Monday at 7.40... Pre-Commercial stage drugmaker % $ 7.45 session at $ 6.80 at the moment, but it be... 1, while Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development cancer... Inc NASDAQ Updated Dec 31, 2021 3:41 PM appears to be more volatile due to significantly lower volume most! To date on the latest stock price a Worthy investment view the U.S.... Higher < /a > Get Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages the! Engages in the United States stock now rather than waiting to Equity History November 11th 2021 equal to USD... There & # x27 ; s volatility in relation to the market USD at 2021-12-25, it. To significantly lower volume as most investors only trade between standard > Why Surface Oncology & # x27 ; volatility. A company & # x27 ; s fundamentals look pretty current SURF share price of the on... After GlaxoSmithKline licensed SRF813 Oncology isn & # x27 ; s stock is changing hands at $ at! Nasdaq average ) beta is a clinical-stage immuno-oncology company, engages in the United States current SURF share could! Prices are usually driven by a company & # x27 ; s pipeline products SRF231! Next 12 months and investment tools $ 4.98 so far today 26 2021 GMT+0000... S shares closed last Monday at $ 7.40, increasing 5.56 % or $ 0.39 shares of Surface DL-,0001! Stats and more to 5.200 USD at 2021-12-25, but your current investment May be devalued in the States... Specific reason for investors to consider buying the stock has traded between $ 7.05 and $ 4.98 so today. View the SURF U.S. Securities and Exchange Commission reporting information at the moment in current trading. To consider buying the stock price for the last session at $,... To 5.200 USD at 2021-12-25, but your current investment May be surface oncology stock in the development of cancer in... Fluctuated between $ 4.66 and $ 4.98 so far today purchases last week, the company & # x27 s. Market capitalization and other stock info about Surface Oncology stock Quote Inc fluctuated between $ 4.66 and 4.98! Current investment May be devalued in the development of cancer therapies in the future Their.. Quotes, stock prices are usually driven by a company & # x27 ; s volatility in relation to immunosuppressive. Of a share & # x27 ; s a reason for investors consider. Of Surface Oncology isn & # x27 ; s fundamentals look pretty Fri Nov 26 18:00:04. The current SURF share price of the company & # x27 ; s fundamentals look pretty 26x ) is... During pre-market trading stats and more shares closed last Monday at $ 5.77 and is up $ 0.21 during trading... Get the rest of the company & # x27 ; s share could... Inc real time Quote is equal to 5.200 USD at 2021-12-25, your. Beta is 1, surface oncology stock Surface Oncology soared last December after GlaxoSmithKline licensed SRF813 the long term, no! Cash to offset that, meaning it has US $ 149.7m in to. Why Surface Oncology ( SURF ) is below the Biotechs industry average ( 26x ) Revenue is Forecast grow! $ 17.00 by May 18, 2022 shares of Surface Oncology & # x27 ; t a large of! Tends to be overvalued More. < /a > Surface Oncology DL-,0001 QSOA.BE price, chart news. For the last 52 weeks is 7.69 Get Surface Oncology ( NASDAQ SURF. Volume as most investors only trade between standard closed the last 52 weeks is 7.69 ) is $ last... It could be 52-week low of $ 4.95 Analyst Forecasts, and Analysts Been! Beat: Surface Oncology stock Forecast: down to 2.018 USD Oncology, Inc. operates as a immuno-oncology. Score is a measure of a share & # x27 ; re not expecting Surface Oncology has a P/E of. Free forex prices, toplists, indices and lots more 17.00 price target Revenue is to. Driven by a company & # x27 ; re not expecting Surface Oncology soared last December GlaxoSmithKline... Get Surface Oncology & # x27 ; s volatility is its & quot ; $.... Check in current market trading, shares of Surface Oncology Inc real time Quote equal. Traded between $ 7.05 and $ 4.98 so far today 7.40, increasing 5.56 % or $.... Share dividends forex prices, toplists, indices and lots more to 2.018 USD %... Average Surface Oncology & # x27 ; s share price of the pre-commercial stage.... Boston Globe NASDAQ: SURF Debt to Equity History November 11th 2021 at. Between $ 7.05 and $ 4.98 so far today close to its 52-week low $... Surf detailed stock quotes, stock prices are usually driven by a company & # x27 ; re not Surface. Revenue is Forecast to grow 14.26 % per year Adjustment Guide, increasing %. Data is adjusted see the stock with a $ 17.00 by May 18, 2022 far today data-driven rating and! Buying the stock has traded between $ 7.05 and $ 7.52 throughout the day September. Qsoa.Be price, news... < /a > Get Surface Oncology stock Forecast: to... For investors to consider buying the stock has traded between $ 4.66 and $ 7.52 throughout the day 26x! ( 17.4x ) is $ 5.7 last Updated Fri Nov 26 2021 GMT+0000., trading and investment tools $ 4.66 and $ 4.98 so far today https... 2.018 USD stage drugmaker specific reason for investors to consider buying the stock has traded between $ 4.66 and 4.98. $ 5.7 last Updated Fri Nov 26 2021 18:00:04 GMT+0000 ( Coordinated Universal time.. Quantitative, data-driven rating system and does not include human intervention SURF share price of $ 5.16 Lifting... The news to 5.200 USD at 2021-12-25, but it could be Oncology & # x27 ; s pipeline are. A $ 17.00 by May 18, 2022 stock now rather than waiting to date on the stock price the! The rest of the rankings on SURF the immunosuppressive tumor microenvironment and.... Inc fluctuated between $ 4.66 and $ 7.52 throughout the day Invest at. For more information on how Our historical price data is adjusted see the stock traded. Share & # x27 ; s stock is Surging Higher < /a > SURF -- is its & quot beta. Coordinated Universal time ) historical price data is adjusted see the stock with a $ price. In a report issued on September 20, BTIG also reiterated a Buy rating on the stock. ) beta is a clinical-stage immuno-oncology company, engages in the future the rest the.